Boston Scientific ($BSX) has scored a win in a Boston court with the dismissal of a class-action lawsuit alleging it had failed to disclose questionable sales practices to investors. The decision comes a year after four pension funds filed suit claiming they had lost more than $2.8 million from buying the company's stock at an artificially inflated price. In his decision, U.S. District Judge Douglas Woodlock said the pension funds' complaint failed to state a "cognizable" claim for securities fraud, Bloomberg notes. Story